Latest Articles
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone - Medpage Today
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone Medpage Today
Published: June 5, 2024, 7 a.m.
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire
Published: June 1, 2024, 7 a.m.
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive
Published: April 24, 2024, 7 a.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network
Published: March 21, 2024, 7 a.m.
Link copied to clipboard!